Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

Hepatology Research

Volumn 46, Issue 5, 2016, Pages 423-433

  Mcewan, Phil ^a,b   Ward, Thomas ^a   Webster, Samantha ^a   Yuan, Yong ^c   Kalsekar, Anupama ^c   Kamae, Isao ^d   Kobayashi, Masahiro ^e   Tang, Ann ^f   Kumada, Hiromitsu ^e  

^a HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e TORANOMON HOSPITAL   (Japan)

^f Healtheconomics Research Group   (Japan)

Author keywords

Chronic hepatitis C; Cost effectiveness analysis; Daclatasvir; Direct acting antivirals

Indexed keywords

ASUNAPREVIR; DACLATASVIR; RIBAVIRIN; SIMEPREVIR; TELAPREVIR;

AGED; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; JAPANESE (PEOPLE); LIFE EXPECTANCY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 84966660791     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12570     Document Type: Article

References (39)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60 (2): 392-420.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5 (9): 558-67.
3. Higuchi M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis 2002; 55 (3): 69-77.
4. Ishida H, Inoue Y, Wong JB, Okita K. Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial. Hepatol Res 2004; 28 (3): 125-36.
5. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53 (1): 39-43.
6. Chayama K, Hayes CN, Ohishi W, Kawakami Y. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol 2013; 48 (1): 1-12.
7. Editors of the Drafting Committee for Hepatitis Management Guidelines. The Japan Society of Hepatology, Guidelines for the Management of Hepatitis C Virus Infection. Hepatol Res 2013; 43 (1): 1-34.
8. Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1. Hepatol Res 2014; 44: 59-70.
9. National Institute of Health and Care Excellence. TA252. Telaprevir for the treatment of genotype 1 chronic hepatitis C. 2012. Available at: http://www.nice.org.uk/ta252. Accessed June 2014.
10. National Institute of Health and Care Excellence. TA253. Boceprevir for the treatment of genotype 1 chronic hepatitis C. 2012. Available at: http://www.nice.org.uk/guidance/ta253. Accessed June 2014.
11. Merck Sharp & Dohme Ltd. Summary of Product Characteristics. Victrelis 200 mg hard capsules. 2013. Available at: http://www.medicines.org.uk/emc/medicine/24768/SPC/Victrelis+200+mg+hard+capsules/. Accessed June 2014.
12. Janssen-Cilag Ltd. Summary of Product Characteristics. Incivo 375 mg film coated tablets. 2013. Available at: http://www.medicines.org.uk/emc/medicine/25038/SPC/INCIVO+375+mg+film+coated+tablets/. Accessed June 2014.
13. Herbst DA, Reddy KR. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013; 22 (10): 1337-46.
14. McPhee F, Sheaffer AK, Friborg J et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012; 56 (10): 5387-96.
15. Suzuki Y, Ikeda K, Suzuki F et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58 (4): 655-62.
16. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59 (6): 2083-91.
17. Asahina Y, Hayashi N, Hiramatsu N et al. JSH guidelines for the management of hepatitis C virus infection (ver 3; abstract). Kango 2014; 55 (10): 634-44.
18. McEwan P, Ward T, Webster S et al. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value in Health Regional Issues 2014; 3: 136-45.
19. McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy 2013; 11 (1): 53-63.
20. McEwan P, Ward T, Yuan Y, Kim R, L'Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013; 58 (1): 54-64.
21. McEwan P, Ward T, Chen C-J et al. Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection. Value in Health Regional Issues 2014; 3: 5-11.
22. McEwan P, Ward T, Bennett H et al. Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C. PLoS One 2015; 10 (1): e0117334.
23. Ministry of Health Labour & Welfare. Japanese life tables. 2014.
24. Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med 2008; 215 (1): 33-42.
25. Ishida H, Terai S, Sakaida I, Inoue Y. Cost-effectiveness of telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. In: The International Society for Pharmacoeconomics and Outcomes Research: Taipei, Japan, 2012.
26. Okita K. Cost effectiveness of hepatocellular carcinoma treatment by disease stage: life expectancy and cost-effectiveness of single tumor by Markov model. Report of MHLW Urgent Measures Against Hepatitis Research Grant. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2007.
27. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20 (11): 2902-12.
28. Broglio K, Quintana M, Kalsekar A, Yuan Y, Berry S. The Comparative Effectiveness of Daclatasvir plus Asunaprevir vs Simeprevir Triple Therapy in Nonresponder Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Bayesian Meta-Analysis. The 24th Annual Conference of Asian Pacific Association for The Study of the Liver; 2015; Istanbul, Turkey.
29. Broglio K, Quintana M, Daar ES et al. Determining Comparative Effectiveness Benchmarks for Emerging Treatments for Hepatitis C Virus (Hcv) Infection in the Single Arm Study Design Setting. Value in Health 17 (3): A2.
30. Broglio K, Daar ES, Yong Y et al. The Comparative Effectiveness of Daclatasvir (DCV) Plus Asunaprevir (ASV) vs Telaprevir (TPV) Triple Therapy in Previously Treated Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Bayesian Meta-Analysis. The 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting; Washington DC, USA; 2013.
31. McPhee F, Sheaffer AK, Friborg J et al. Elderly and Cirrhotic Patients Without Baseline NS5A Polymorphisms in HCV Genotype 1b Have Very High Sustained Virologic Responses to Daclatasvir Plus Asunaprevir. In 24th Conference of the Asian Pacific Association for the Study of Liver. Istanbul, Turkey, 2015.
32. Martinot-Peignoux M, Stern C, Maylin S et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51 (4): 1122-6.
33. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010; 19 (4): 422-37.
34. Lok AS, Gardiner DF, Hézode C et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60 (3): 490-9.
35. Manns M, Pol S, Jacobson IM et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384 (9954): 1597-605.
36. Chayama K. All-oral Dual Combination of Daclatasvir plus Asunaprevir Compared with Telaprevir plus Peginterferon Alfa/Ribavirin in Treatment-naive Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Phase 3 Study. In AASLD. Boston, MA, 2014.
37. Imazeki F, Yokosuka O, Fukai K et al. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int 2005; 25 (4): 772-8.
38. Hayashida K, Nagasue I, Fukuda T, Gunji A. The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment. J Epidemiol 2002; 12 (1): 22-32.
39. Arase Y, Kobayashi M, Suzuki F et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57 (3): 964-73.